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In several laboratory meetings, we discussed the challenges that face trainees in behavioral
pharmacology. Major concerns, such as a difficult funding climate and limited academic job
prospects were discussed at first. However, we decided to concentrate on ways to meet these
challenges; versus focusing on negatives and listing gripes. Within this more constructive
framework, we identified the importance of broadening training to aligned areas to enhance the
capacity of behavioral pharmacologists to collaborate in multidisciplinary teams. With increased
breadth of training comes the concern for a balance that does not cheat trainees out of the depth of
training also needed for success. We believe that behavioral pharmacologists trained in this
manner will be ideally positioned to be leaders of these translational research teams. Related to the
breadth and depth of training is the recent concerns over replicability and reproducibility of
published research. Behavioral pharmacologists, with the rigors of training in behavioral analysis
and experimental design, can be at the forefront of this conversation. This will be especially true if
current training is reinforced with additional experience in the use of cutting-edge statistical tools
that address the complex experimental designs and large data sets that emerge from modern
multidisciplinary collaborations. Finally, communicating the import and potential societal impact
of our research to legislators, other scientists, educators, school children, neighbors, and
acquaintances is needed to ensure that our field thrives. In closing, the process of explicitly
discussing the challenges and potential solutions with current trainees will enhance their
mentoring and training.

Evolving Conversations

Author Manuscript

The request from Dr. Alan Poling for contributions to this special section asked for
reflections on “the defining features of behavioral pharmacology, its current status, and its
probable future, including if possible consideration of areas where growth is possible.” I
(Bevins) brought this suggestion to my laboratory crew and this sparked a thoughtful series
of evolving conversations on a range of topics. The first conversation or two occurred at the
closure of a laboratory meeting with 10 or 15 minutes left. Interestingly, in this brief time,
the tone of the topics went quite negative. For example, and perhaps not surprising, one topic
that recurred was the continuing poor budget outlook for the National Institutes of Health
(NIH). What does this budget situation mean for early career investigators trying to establish
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independent programs of research? Will this funding environment be cyclic or is this a new
normal? If the latter, what does this mean for current and future trainees. Does the limited or
lack of a science education received by most of our legislature, and the public in general,
contribute to this situation? Perhaps related, there seems to be a dwindling number of job
prospects, relative to the number of behavioral pharmacologists currently being trained.
Although there are notable strongholds for academically-oriented behavioral
pharmacologists within certain universities and medical centers, more often than not, our
impression was that these positions were lost or reallocated to fields of neuroscience with a
more molecular focus and often with little to no consideration of behavioral processes.
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Rather than 15 minutes of a laboratory meeting here and 10 minutes there, we eventually
decided to sit down and dedicate several lengthy discussions to this topic. We also decided to
avoid negativity and frame the conversation in a more positive and constructive light. For
example, instead of complaining about the reallocation of jobs, we should talk about how we
compete successfully for those jobs, while maintaining our core identity as a behavioral
pharmacologists. Similarly, how can we position ourselves to be more successful at
competing for the limited grant dollars from NIH or other extramural funding agencies? The
narrative that follows reflects a winnowed version of these conversations1.

Laboratory Notes
Breadth of training
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By definition, behavioral pharmacology, since its inception, has been a multidisciplinary
field. Today, the study of the effects of drugs on the brain and behavior can include such
disciplines as psychology, pharmacology, neuroscience, chemistry, genetics, economics,
evolutionary biology, sociology, computer science, and biomedical engineering. As the field
of behavioral pharmacology moves forward, and as our understanding of the varied
mechanisms of behavior expands, the need for individual researchers to become better
versed in a wide range of theoretical and methodological approaches also expands. To meet
these challenges and to remain competitive, the training for future (and current) behavioral
pharmacologists ought to increase the breadth of topics to which trainees are exposed. Such
training may equip individuals with the skills increasingly requisite for reviewing and
conducting rigorous and informative science. Indeed, investigators who are versed in a wider
array of applicable topics may be better positioned to help tackle complex scientific
questions traditionally, and perhaps not traditionally, in the purview of behavior
pharmacology. Such researchers are a boon on grant review panels, and as members of a
research team. They are able to integrate a wider array of pertinent knowledge from an
expanse of disciplinary approaches to ensure that our field continues to conduct science with
the highest rigor, innovation, and application.
1To better understand the conversation, we thought it would be helpful if the reader knew where each author was in their training. Rick
Bevins, as the PI of the Behavioral Neuropharmacology Laboratory (BNL), published his first behavioral pharmacology paper in
1994. He has been on the faculty at the University of Nebraska-Lincoln (UNL) since 1996. Scott Barrett received his Bachelor’s
degree at Utah State University working in the laboratory of Dr. Amy Odum. He completed his Ph.D. in 2015 at UNL and is now a
post-doctoral scholar in the laboratory. Steven Pittenger received his Bachelor’s degree at Kansas State University working in the
laboratory of Dr. Mary Cain. He is finishing his dissertation and will be starting a post-doctoral position with Dr. Marina Picciotto at
Yale in August 2016. Brady Thompson finished his Bachelor’s degree at Nebraska Wesleyan University last year and is now a
technician and manager in the BNL and an incoming graduate student.
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With the need to expand training in an increasingly broad range of research fields also
comes a need to ensure and to protect depth of training. Herein lies the challenge for
trainees, mentors, and graduate programs: ensuring an increased breadth of training, while
simultaneously maintaining quality and depth of training that has been the hallmark of
behavior pharmacology. Meeting this challenge will not be easy and it will require constant
vigilance to avoid training that produces behavioral pharmacologists that are “jack-of-alltrades, masters-of-none.” On the other end of the continuum, we must avoid such narrow
training that the individual is trapped in the ivory tower of the academy and unable to work
on a research team addressing pressing scientific questions outside the comfortable
boundaries of traditional training. If the balance is struck and we are successful, then the
field of behavioral pharmacology will thrive. Indeed, to the extent that research in the field
increasingly employs multidisciplinary approaches to a host of important societal issues,
then institutional research teams, grant review committees, and editorial boards require
individuals who are well-versed in a wide arrange of topics, but also highly knowledgeable
in the area of their specialty.
Research teams
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The idea that an individual could achieve expert status across all fields potentially interested
in the discoveries of behavioral pharmacology research is by most standards, an
unreasonable, if not impossible, expectation. This fact alone calls for a cohesive plan by
experts to collaborate in a meaningful manner to solve complex societal questions. We have
referred to scientific teams several times in these notes. However, to address the most
complex and vexing problems facing society today will require an approach where scientific
questions and answers move seamlessly across the disciplines and are addressed at each
level in a manner communicable, useful, and informative to the other levels. For many
health-related questions (e.g., drug abuse, obesity, schizophrenia, etc.), a behavioral
pharmacologist trained in the manner we have been discussing would likely serve as a
linchpin team member. Take as an example substance abuse with its estimated societal cost
of $600 billion dollars a year (NIH, 2013). A behavioral pharmacologist could be ideally
positioned to gather researchers that span public policy, intervention and prevention
development, community-based participatory research, neuroimaging, behavioral
pharmacology, neurobiology, genetic, and medicinal chemistry to answer an integrated set of
questions central to the etiology of substance abuse. This approach is not novel per se, as
there are a number of centers and program projects of this nature funded by the National
Institute on Drug Abuse (NIDA). However, what we are suggesting is that behavioral
pharmacologists seek training that will place them as leaders of such efforts.
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Replication and reproducibility
Trainees in the field will continue to require rigorous instruction in the scientific method and
hypothesis testing to ensure that future research in behavioral pharmacology persists as
innovative, illuminating, and informative. Recently reported issues regarding scientific rigor
and reproducibility highlight the need for current and future researchers to be trained in
sound scientific design and state-of-the-art analytical approaches (Prinz et al., 2011;
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"Trouble at the Lab," 2013). Experimental analysis of behavior must be a key component of
that training. However, an exclusive focus on this area will not be enough. For example,
imagine a self-administration study that combines testing the effectiveness of a potential
medication to prevent reinstatement with a proteomic approach to begin identifying potential
neural mechanisms of the drug’s action. The very nature of this hypothetical study (i.e., very
large data set from the gene assay), combined with the desire to ensure the continued
reproducibility and reliability of our work, prompts the need to use statistical procedures that
appropriately account for errors in hypothesis testing. Further, leveraging recent advances
and up-to-date statistical methods such as multilevel regression modeling and robust
estimation will keep the field on the cutting-edge and aid in achieving our goals.
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Greater emphasis needs to be placed on the detailed reporting of methodological practices.
Publications in some of our most highly-regarded periodicals are often severely lacking in
detail, making the results difficult to evaluate or reproduce. There is enough blame to go
around. The journals put significant restrictions on manuscript length and word count, thus
forcing authors to make compromises to meet those requirements. In an era of online
publishing, DOIs, and PDFs, this practice seems antiquated and makes little sense. Of
course, investigators could make better use of supplemental section when available in a
journal. Additionally, we should take care to write the methods section from the perspective
of someone in a different laboratory that wants to replicate and extend the study. Sometimes
small details that are routine in a laboratory, and could be easily overlooked, may matter for
replication. For example, a small detail in our intravenous drug self-administration protocol
is that we start each session with a priming infusion that fills the internal volume of the
indwelling jugular catheter (Charntikov et al., 2015). This step has the effect of more closely
equating the volume of drug delivered into the vein on the first earned infusion with the
volume of later infusions. Not only do we believe it is good scientific practice to control
such factors when possible, we also believe that it matters and may affect behavioral or
neuropharmacological outcomes.
Better communication
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One of the major recurring themes of our discussions for this commentary was the critical
need for behavioral pharmacologists to openly engage in scientific communication at
multiple levels. The NIH budget has stagnated over the past decade. Not only has funding
not adjusted for inflation ($28.1 billion in 2004 to $30.1 billion in 2014), but it has actually
decreased in real dollars ($31 billion in 2010) over the past five years (NIH, 2015). It is
imperative that we communicate with our congressional delegations the benefits of a wellfunded scientific community and highlight the importance of basic scientific research to the
long-term health and well-being of society, as well as the economic impact of these
advances. Notably, some allied professional societies (e.g., American Psychological
Association [APA], American Society for Pharmacology and Experimental Therapeutics
[ASPET], Society for Neuroscience [SfN]), provide fellowships and/or workshops that
inform scientists on best practices for more effectively communicating with legislators.
As behavioral pharmacologists, we will also need to actively convey the importance of our
field to scientific colleagues in other disciplines when given the opportunity. A deeper
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appreciation of behavioral pharmacology may serve us well when these colleagues are
serving on Center for Scientific Review (CSR) Study Sections for NIH. Finally, scientific
communication with our local community is a necessity. The measles outbreak in December
2014 – January 2015 sourced to Disney theme parks in Orange County, California, and
spread largely by unvaccinated individuals, provides an alarming example of how scientific
repudiation is a grave public health concern (Zipprich et al., 2015). Community outreach in
the form of public forums, guest teaching in our local science classrooms, as well as
informal discussions with our friends and family will help educate the public on the
scientific process and instill trust in science and its outcomes. The Society for Neuroscience
has Brain Awareness Week and, as an example, provides many supports for how to engage
children and teachers in public schools about the benefits of neuroscience research. Perhaps
we can steal a page from their playbook and encourage the leaders of our scientific
organizations (e.g., Division 28 [Psychopharmacology and Substance Abuse] of the APA or
the Behavioral Pharmacology Society) to coordinate such efforts. Interaction with members
of our community may also come in the form of outreach through social media. Behavioral
pharmacologists publishing books targeted at non-scientist may also increase accessibility
and appreciation of our field. A well-informed public may even aid in the expansion of
government funded scientific research. The bottom line here is that communication at all
levels, local to federal, is paramount to the success of the field of behavioral pharmacology,
and science in general.

Closing Reflections
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I (Bevins) recommend that every laboratory PI prompt this conversation every so often. We
frequently have informal conversations about the current status and the future of behavioral
pharmacology, but there is something different about formalizing the discussion. It was
illuminating to hear what topics and concerns were on the minds of my trainees. The
positive framing for solutions was constructive. Perhaps some of the issues were predictable
and stand the test of time (e.g., availability of jobs). However, each trainee differs and the
potential constructive solutions or actions for that future behavioral pharmacologist may
differ from past trainees. Regardless, these types of conversations can inform mentoring and
recommendations for training in an ever evolving field. Finally, thanks to Dr. Poling for
prompting these conversations; they were eye opening.
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